/ News

News

We deliver cutting-edge diagnostic solutions. Here, you will find timely updates and breakthroughs in our efforts to empower healthcare professionals across the globe, in diagnosing and monitoring blood cancers and immune system disorders. 

Results Found:
March is Myeloma Action Month
March is Myeloma Action Month
We are excited to announce our partnership with the International Myeloma Foundation to promote better understanding of Multiple Myeloma, raise awareness of the disease, its symptoms, and appropriate tests to order can lead to earlier diagnosis and better outcomes for patients.
EXENT® System now available in Australia and New Zealand
EXENT® System now available in Australia and New Zealand
Building on the clinical validation and IVDR Certification of the EXENT® System, Binding Site, part of Thermo Fisher Scientific has now received regulatory authorization for the clinical use of the solution in Australia.
Blood Cancer Awareness Month
Blood Cancer Awareness Month
Blood Cancer Awareness Month is taking place in September, and we are thrilled to announce our partnership with the International Myeloma Foundation to shine a spotlight on blood cancer and raise the profile of Multiple Myeloma, the second most common blood cancer.
Onco Tracker Collaboration
Onco Tracker Collaboration
sBCMA test may both monitor and predict outcomes in multiple myeloma and other blood cancers ONCOtracker.
iStopMM Trial Methods Paper Publication
iStopMM Trial Methods Paper Publication
Binding site is pleased to announce that the methods paper for the landmark iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) study has now been published.
Launch of the EXENT® Solution with IVDR Certification Announced
Launch of the EXENT® Solution with IVDR Certification Announced
Transforming monoclonal gammopathy management to address an unmet clinical need through an innovative mass spectrometry solution.
Thermo Fisher Scientific Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS, a Precursor to Multiple Myeloma
Thermo Fisher Scientific Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS, a Precursor to Multiple Myeloma
Thermo Fisher Scientific Inc. announces 510k clearance to market its Optilite® Freelite® assays’ claim for the evaluation of monoclonal gammopathy of undetermined significance (MGUS).
Thermo Fisher Scientific to Acquire The Binding Site Group
Thermo Fisher Scientific to Acquire The Binding Site Group
Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma.
Mark Stevenson
Mark Stevenson
The Binding Site, a global leader in specialist protein diagnostics, has appointed Mark Stevenson as new non-executive Chairperson.